Calmark signs agreement regarding equipment for automation of production line
Today, Calmark Sweden AB and Automations Partner i Helsingborg Aktiebolag signed an agreement regarding the construction of the machines for the fully automated production line for the single-use tests.
As previously disclosed, a decision was adopted on April 16 to bring forward the investment in expanded production capacity in order to accelerate the production of higher volumes and significantly reduce the manufacturing cost per unit. The Company has concluded an agreement with SEB, Skandinaviska Enskilda Banken AB (publ), relating to leasing of the production equipment.
The agreement concluded with Automationspartner today comprises all the machinery required for automation of the remaining manual stages of the manufacturing process. The equipment will be installed at Calmark's production partner, Frohe AB in Tyresö. Following the implementation, production capacity will increase thirteenfold compared with current levels.
"I am delighted that we have reached this agreement with Automationspartner, which will give us a dramatic improvement of production capacity and a much more cost-efficient production of our single-use tests as early as next year," says Anna Söderlund, CEO of Calmark. "This offers us a good position to succeed with the global market launch of our products that we now are getting underway."
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se
www.calmark.se
Calmark Sweden AB is a medical technology company developing a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a reader and single-use products. The first three tests are being launched in 2020. WHO expects 1.5 billion children to be born worldwide prior to 2030. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer decision-making support, which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.
Tags: